Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with chemoradiotherapy for larynx preservation in hypopharyngeal and laryngeal cancer
ChiCTR-IIR-16007712Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Feb 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of nimotuzumab in laryngeal squamous cell carcinoma (LSCC) and squamous cell carcinoma of the hypopharynx (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Larynx preservation and Safety. Started Feb 2013; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
laryngeal squamous cell carcinoma (LSCC)squamous cell carcinoma of the hypopharynx
Beyond the preview
Go deeper on ChiCTR-IIR-16007712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16007712.